KASEB-BIOMARKER-ANALYSIS

NCT03222076 📎

Regimen

Experimental
neoadjuvant nivolumab +/- ipilimumab (biomarker substudy)

Population

Biopsy-proven resectable hepatocellular carcinoma (N=18 biomarker substudy of Kaseb 2022 Lancet Gastroenterol Hepatol trial)

Key finding

MPR responders had ↑ intratumoral CD8 (+26.9%), granzyme B (+15.6%), PD-1 (+20.2%) post-treatment. Baseline tumour size and dynamic immune infiltration as candidate predictive biomarkers for perioperative IO response.

Source: PMID 39427654

Timeline